Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals

Andrea Lombardi\textsuperscript{a,b,*}, Dario Consonni\textsuperscript{c,1}, Massimo Oggioni\textsuperscript{d}, Patrizia Bone\textsuperscript{d}, Sara U. Renteria\textsuperscript{d}, Alessandra Piatti\textsuperscript{e}, Angela C. Pesatori\textsuperscript{c,f}, Silvana Castald\textsuperscript{g,h}, Antonio Muscatello\textsuperscript{a}, Luciano Riboldi\textsuperscript{i}, Ferruccio Ceriotti\textsuperscript{d}, Alessandra Bandera\textsuperscript{a,b,j}, Andrea Gori\textsuperscript{a,b,j}

\textsuperscript{a} Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
\textsuperscript{b} Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
\textsuperscript{c} Epidemiology Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
\textsuperscript{d} Clinical Laboratory, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
\textsuperscript{e} Medical Direction, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
\textsuperscript{f} Department of Clinical Sciences and Community Health, University of Milano, Milan, Italy
\textsuperscript{g} Department Biomedical Sciences for Health, University of Milano, Milan, Italy
\textsuperscript{h} Quality and Internal Audit Privacy Unit, University of Milano, Milan, Italy
\textsuperscript{i} Occupational Health Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
\textsuperscript{j} Centre for Multidisciplinary Research in Health Science (MACH), University of Milano, Milan, Italy

A R T I C L E   I N F O

Article history:
Received 24 May 2021
Received in revised form 3 July 2021
Accepted 7 July 2021

Keywords:
COVID-19
Vaccination
Healthcare workers
BNT162b2

A B S T R A C T

Great expectations are placed in vaccines against COVID-19 to control the pandemic. We reviewed the antibody titres in a cohort of healthcare workers (HCWs) vaccinated with BNT162b2 to assess the influence of a previous infection on them. We stratified the results according to the individual history of nasopharyngeal swab (NPS) and symptoms. Among 3475 HCWs the highest titres were recorded among those infected more than 6 months before vaccination, independently of symptoms, followed by those infected less than 6 months before vaccination, especially in those with symptoms, and by uninfected HCWs. Vaccination with BNT162b2 can boost immunity acquired through infection, particularly in those infected more than 6 months before vaccination.

© 2021 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

I N T R O D U C T I O N

The pandemic of Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2), is hardly affecting the entire world, with 155,373,584 cases and 3,245,391 related deaths as of 11th of May 2021 and great expectations are placed in mass vaccination. Currently, the four COVID-19 vaccines approved in the European Union are the mRNA-based BNT162b2 and mRNA-1273 and the adenoviral vector-based ChAdOx1 nCoV-19 and Ad26.COV2-S [1]. All these vaccines are designed to elicit an immune response directed toward the S1 spike protein of SARS-CoV-2 [2]. Both BNT162b2 and mRNA-1273 in the first 100 days after vaccination were able to elicit specific antibodies titres and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum [3]. Uncertainties remain regarding the impact of vaccination of previously infected individuals, with preliminary data showing higher antibody titres in those who were infected [4–7]. Moreover, the severity of COVID-19 has been directly correlated with the persistence of detectable neutralizing antibodies in serum [8].

M E T H O D S

We assessed the anti-S1 antibody titres (Elecsys Anti-SARS-COV-2 S, Roche Diagnostics, Monza, Italy) on 3475 healthcare workers (HCWs) of the IRCCS Ospedale Maggiore Policlinico of Milan, Italy, 28 days after having received the second dose of BNT162b2 vaccine (data as of May 1). All the HCWs received two doses of BNT162b2 vaccine, irrespective of previous SARS-COV-2
Infection, 21 days apart. We reviewed the results of SARS-CoV-2 RT-PCR on nasopharyngeal swabs (NPSs) (AllplexTM2019-nCoV Assay, Seegene, Seoul, South Korea) performed for active surveillance, presence of symptoms or contact with COVID-19 case, by the vaccinated HCWs since the beginning of the COVID-19 pandemic. We examined the association of anti-S1 titres with gender, age, BMI, smoking, and a five-category variable representing the combination of NPS results and symptoms, i.e., never positive, positive less than 180 days before Ig testing (without or with symptoms), positive more than 180 days before (without or with symptoms). Those infected less than 180 days before Ig testing were defined as recently infected whereas those receiving immunosuppressive drugs for transplantation or autoimmune disorders were classified as with immune deficiencies. We used Kruskal–Wallis test to analyse quantitative titres and chi-squared test to analyse above the higher measurement limit (HML) of the method (7500 U/mL). Finally, we fitted a multivariable Poisson regression model with robust standard error containing all these variables to calculate adjusted risk ratios (RR) and 95% confidence intervals (CI) of high (i.e., >HML) vs low titres. Analyses were performed with Stata 16 (StataCorp. 2019) [9]. The study was exempted from a formal approval by the internal review board of our institution considering that the results are aggregate data collected for health surveillance purposes.

## Results

Out of 3475 subjects, only six (0.17%) had non-detectable anti-S1 (i.e., less than the limit of quantification of <0.4 U/mL), four of them reported underlying immune deficiencies. Median anti-S1 titres (Table 1) were associated with age (negatively) and BMI (positively). Smokers showed lower median titres than never smokers. Subjects who never had positive NPS tests had the lowest median titres. Asymptomatic subjects infected less than six months before Ig testing had lower median titres than recently infected symptomatic ones and those infected more than six months before. When analysing crude proportions of high (>HML) titres, the associations with BMI and smoking were confirmed. Moreover, we found a positive trend with NPS results and symptoms: 6.7% had high anti-S1 among never positives, 25.7% among asymptomatic recently infected, 59.4% among symptomatic recently infected, and about 90% (irrespective of symptoms) in those infected more than six months before. The multivariable analysis confirmed that subjects aged <35 years, overweight/obese, and never smokers had higher frequency of high (>HML) titres. Also confirmed was the pattern according to NPS results and presence of symptoms.

## Discussion

Our serologic data suggest that the complete vaccination schedule with BNT162b2 elicits a vigorous immune response, assessed in terms of raw anti-S1 antibody titres, in both uninfected and previously exposed individuals. This response appears higher in those who were infected more than 6 months before vaccination than those infected more recently. Interestingly, the highest antibody titres were found among those aged <35 years, those overweight/obese, and who never smoked. Among those infected, antibody titres above the HML were associated with the presence of symptoms.

The detection of higher antibody titres among subject previously infected is an expected finding, with the vaccination acting as a booster of naturally occurring immunity. Overall, our data are in accordance with preliminary reports already available [4–7]. Several reasons can justify the higher antibodies titres observed in the

### Table 1

| Variable                  | N subjects | Anti-S (U/mL) Median | Anti-S>7500 U/mL | % | RR   | 95% CI |
|--------------------------|------------|----------------------|------------------|---|------|--------|
| All                      | 3475       | 1577                 | 530              | 15.2 |      |        |
| Gender                   |            |                      |                  |    |      |        |
| Women                    | 2475       | 1602                 | 358              | 14.5 | 1.00 | Reference |
| Men                      | 1000       | 1501                 | 172              | 17.2 | 1.00 | 0.87–1.15 |
| **p-Value**              |            | 0.10                 |                  |    |      |        |
| Age (years)              |            |                      |                  |    |      |        |
| <35                      | 1162       | 1976                 | 194              | 16.7 | 1.00 | Reference |
| 35–44                    | 669        | 1553                 | 88               | 13.1 | 0.67 | 0.55–0.82 |
| 45 + 54                  | 903        | 1449                 | 134              | 14.8 | 0.72 | 0.60–0.86 |
| 55+                      | 741        | 1208                 | 114              | 15.4 | 1.00 | 0.66–0.94 |
| **p-Value**              |            | 0.001                |                  |    |      |        |
| BMI (kg/m²)              |            |                      |                  |    |      |        |
| <20                      | 602        | 1487                 | 75               | 12.5 | 1.00 | Reference |
| 20–24.99                 | 1612       | 1556                 | 229              | 14.2 | 1.00 | 0.80–1.24 |
| 25–29.99                 | 765        | 1556                 | 127              | 16.6 | 1.20 | 0.95–1.54 |
| 30+                      | 266        | 2029                 | 60               | 22.6 | 1.34 | 1.02–1.76 |
| **p-Value**              |            | 0.004                |                  |    |      |        |
| Cigarette smoking        |            |                      |                  |    |      |        |
| Never                    | 1908       | 1756                 | 342              | 17.9 | 1.00 | Reference |
| Former                   | 567        | 1514                 | 83               | 14.6 | 0.85 | 0.71–1.02 |
| Current                  | 804        | 1218                 | 71               | 8.8  | 0.63 | 0.51–0.77 |
| **p-Value**              |            | 0.001                |                  |    |      |        |
| Nasopharyngeal swab/symptoms |         |                      |                  |    |      |        |
| Never positive           | 2968       | 1374                 | 200              | 6.7  | 1.00 | Reference |
| Positive <180 days before/No | 70  | 2589                 | 18               | 25.7 | 3.67 | 2.27–5.93 |
| Positive <180 days before/Yes | 271  | 7500                 | 161              | 59.4 | 9.00 | 7.55–10.7 |
| Positive 180+ days before/No | 14  | 7500                 | 12               | 85.7 | 11.5 | 8.1–16.4 |
| Positive 180+ days before/Yes | 152  | 7500                 | 139              | 91.4 | 13.3 | 11.3–15.7 |
| **p-Value**              |            | 0.0001               |                  |    |      |        |

Abbreviations: BMI, body mass index; CI, confidence interval; LOQ, limit of quantification; RR, risk ratio.

RR were calculated with a multivariable Poisson regression model with robust standard error containing all the variables in the table.

* Higher measurement limit: 7500 U/mL.

** p-Values calculated with Kruskal–Wallis (quantitative titres) or chi-squared (titres > LOQ) tests.
NPS $\geq 180$ group. On one hand, they can be the consequence of multiple exposures to SARS-CoV-2 occurred after the first infection, which acted as natural boosters of the immune response. On the other hand, it is well known how high recall and anamnestic responses to vaccination are associated with intervals of at least 3–4 months between stimuli, with longer intervals associated with generally greater responses. On the basis of our results, previously infected individuals can be vaccinated with the reassurance of achieving elevated antibody titres.

Regarding the highest titles observed among those who presented symptoms, this parallel similar observations that our and other groups have made also for anti-N antibodies, elicited only by natural infection [10]. Among the other, Legros et al. demonstrated how neutralizing antibodies (nAbs) titres correlated strongly with disease severity and with anti-spike IgG levels, with patients from intensive care units exhibiting high nAb titres whereas asymptomatic or exclusive outpatient-care patients had no or low nAbs [11]. It remains to be understood if vaccination can elicit nAbs in previously infected individuals in the same way that anti-S1 antibodies are stimulated.

Interestingly, as we previously observed for anti-N antibodies, anti-S1 antibodies titres were lower among smokers [10]. This confirm the impact of smoking on the immune system and its ability to mount an humoral response to inhaled but also injected antigens, a finding in contrast with previous evidence which suggested an influence only on inhaled antigens [12]. Cumulatively, smokers are particularly at risk during COVID-19 pandemic for both the increased probability of having respiratory manifestations and the lower ability of mounting an effective immune response.

Intriguingly is the positive association found between the anti-S1 antibody titre and the BMI. Indeed, SARS-CoV-2 IgG antibodies have been negatively associated with BMI in COVID-19 obese patients [13]. This is in accordance with what has been observed after influenza infection or influenza vaccination, which has been linked to the higher inflammation, the reduced number of suppressive T-regulatory cells and the decreased populations of bone marrow–resident B cells observed among obese individuals [14,15]. After influenza vaccination in obese patients, BMI was correlated positively with higher initial fold increase in IgG antibodies but, 12 months post vaccination, higher BMI was associated with a greater decline in influenza antibody titres. A similar trend could be expected in our cohort and a long term follow-up of antibody titres is needed to verify this hypothesis.

Several questions remain unanswered: the duration of the antibody response, the cellular immune response elicited, the minimum titre required to be protected from COVID-19, the effectiveness of vaccination against SARS-CoV-2 variants and the prevalence of neutralizing antibodies among the total value of antibodies. Overall, vaccination with BNT162b2 elicited strong antibody responses in both previously infected and uninfected individuals and this response was particularly relevant among those recently infected who reported symptoms and in those with remote infection, irrespective of symptoms.

Competing interests
None declared.

Ethical approval
Not required.

Acknowledgments
This study was partially supported by Ministry of Health RC 2021 and by Intesa San Paolo 2020 Fund.

References
[1] COVID-19 vaccines authorised for use in the European Union. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-2019-treatments/vaccines/covid-19-vaccines.
[2] Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med 2021;384(6):533–40, http://dx.doi.org/10.1056/NEJMoa2034545. Epub 2020 Dec 23. PMID: 33693636; PMCID: PMC7781098.
[3] Lombardi A, Bozzi G, Ungaro R, Villa S, Castelli V, Mangioni D, et al. Mini Review Immunological Consequences of Inflammation With COVID-19 mRNA Vaccines: Preliminary Results. Front Immunol 2021;12:657711, http://dx.doi.org/10.3389/fimmu.2021.657711. PMID: 33777055; PMCID: PMC7994748.
[4] Manisty C, Otter AD, Treibel TA, McKnight A, Altmann DM, Brooks T, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet 2021;397(10257):1057–8. Epub 2021 Feb 25. PMID: 33640038; PMCID: PMC7972310.
[5] Krammer F, Srivastava K, Alishammari H, Amoako AA, Awadwa MH, Beach KF, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med 2021;384(14):1372–4, http://dx.doi.org/10.1056/NEJMoa2101667. Epub 2021 Mar 10. PMID: 33691060; PMCID: PMC8008743.
[6] Ebinger JF, Fert-Boyer J, Prinsvist I, Wu M, Sun N, Prostko J, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med 2021;27(6):981–4, http://dx.doi.org/10.1038/s41591-021-01325-w. Epub 2021 Apr 1. PMID: 33795870; PMCID: PMC8208540.
[7] Anichini G, Terrosi C, Gandolfi C, Gori Savellini G, Faletti S, Miceli GB, et al. SARS-CoV-2 Antibody Response in Persons with Past Natural Infection. N Engl J Med 2021;385(1):90–2, http://dx.doi.org/10.1056/NEJMct2103825. Epub 2021 Apr 14. PMID: 33852786; PMCID: PMC8063888.
[8] Lai EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. Nat Commun 2021;21(1):63, http://dx.doi.org/10.1038/s41467-020-20247-4. PMID: 33397905; PMCID: PMC7782739.
[9] Lombardi A, Consonni D, Carugno M, Bozzi G, Mangioni D, Muscatello A, et al. Characteristics of 1573 healthcare workers who underwent nasopharyngeal swab testing for SARS-CoV-2 in Milan, Lombardy, Italy. Clin Microbiol Infect 2020;26(10):1413.e9–13, http://dx.doi.org/10.1016/j.cmi.2020.06.013. Epub 2020 Jun 20. PMID: 32568935; PMCID: PMC7305713.
[10] Lombardi A, Mangioni D, Consonni D, Caruni I, Bono P, Cantù A, et al. Seroprevalence of anti-SARS-CoV-2 IgG among healthcare workers of a large university hospital in Milan, Lombardy, Italy: a cross-sectional study. BMJ Open 2021;11(2):e047216, http://dx.doi.org/10.1136/bmjopen-2020-047216. PMID: 33619203; PMCID: PMC902322.
[11] Legros V, Denollet S, Vogrig M, Boson R, Siret E, Rigaud J, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol 2021;18(2):318–27, http://dx.doi.org/10.1038/s41423-020-00588-2. Epub 2021 Jan 6. PMID: 33408342; PMCID: PMC7786875.
[12] Andersen P, Pedersen OF, Bach B, Bonde GJ, Serum antibodies and immunoglobulins in smokers and nonsmokers. Clin Exp Immunol 1982;47:467–73.
[13] Frasca D, Reidy L, Cray C, Diaz A, Romero M, Kahn K, et al. Influence of obesity on serum levels of SARS-CoV-2-specific antibodies in COVID-19 patients. PloS One 2021;16(2):e0245424, http://dx.doi.org/10.1371/journal.pone.0245424. PMID: 33760825; PMCID: PMC799309.
[14] Sheridan PA, Paich HA, Handy J, Karlsson EA, Hugdens MG, Sammon AB, et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int J Obes (Lond) 2012;36(8):1072–7, http://dx.doi.org/10.1038/ijo.2011.208. Epub 2011 Oct 25. PMID: 22024641; PMCID: PMC3270113.
[15] Green WD, Beck MA. Obesity impairs the adaptive immune response to influenza virus. Ann Am Thorac Soc 2017;14:5406–9.

Contributors
AL, DC and AG conceived the study. PB, SUR, DC, FC, MO collected the data. DC performed statistical analysis. AL wrote the first draft of the manuscript. All the authors reviewed the final version of the manuscript.